Aquestive reports positive human factors and PK results for Anaphylm film
Aquestive Therapeutics announced positive human factors and pharmacokinetic study results for its Anaphylm (dibutepinephrine) sublingual film, supporting its planned NDA resubmission in Q3 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day